News
PRTK
2.090
-0.95%
-0.020
BAND, PRTK and OTLY are among after hour movers
Seeking Alpha · 1d ago
BRIEF-Paratek Pharmaceuticals Announces Inclusion Of Nuzyra In China’S National Reimbursement Drug List
Reuters · 01/18 13:52
Paratek/ Zai Lab antibiotic added for reimbursement in China
Seeking Alpha · 01/18 12:19
Paratek Pharmaceuticals Announced Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List
Benzinga · 01/18 12:04
H.C. Wainwright Remains a Buy on Paratek Pharmaceuticals (PRTK)
TipRanks · 01/09 11:15
BRIEF-Paratek Pharmaceuticals Receives $36.4 Mln Milestone Payment Associated With Nuzyra
Reuters · 01/05 14:00
Paratek Pharmaceuticals Receives $36.4M Milestone Payment Associated With The Second Procurement Of NUZYRA Under BARDA Project BioShield Contract
Benzinga · 01/05 13:06
Paratek Pharmaceuticals Gets $36.4 Million Milestone Payment From Second Procurement of Nuzyra Under BARDA Contract
Paratek Pharmaceuticals Gets $36.4 Million Milestone Payment From Second Procurement of Nuzyra Under BARDA Contract
MT Newswires · 01/05 12:23
Paratek Pharmaceuticals Announces Top Line Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax And Acceptance Of The Second Procurement Of NUZYRA Under BARDA Project BioShield
Benzinga · 12/19/2022 12:37
BRIEF-Paratek Pharmaceuticals Announces Positive Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax
Reuters · 12/19/2022 12:34
Paratek Pharmaceuticals Says Positive Data From Nuzyra Study to Treat Anthrax Triggers $38.1 Million Procurement
Paratek Pharmaceuticals Says Positive Data From Nuzyra Study to Treat Anthrax Triggers $38.1 Million Procurement
MT Newswires · 12/19/2022 10:06
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other pub...
GlobeNewswire · 12/01/2022 22:45
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Benzinga · 11/04/2022 16:54
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03/2022 21:45
Paratek Pharmaceuticals Q3 EPS $(0.38) Misses $(0.29) Estimate, Sales $30.21M Miss $34.19M Estimate
Benzinga · 11/03/2022 20:43
Paratek Pharmaceuticals GAAP EPS of -$0.38, revenue of $30.2M
Seekingalpha · 11/03/2022 20:26
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax -- Announced Comm...
GlobeNewswire · 11/03/2022 20:05
-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q3 Revenue $30.2M
-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q3 Revenue $30.2M
MT Newswires · 11/03/2022 16:34
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other pub...
GlobeNewswire · 11/01/2022 12:00
More
Webull provides a variety of real-time PRTK stock news. You can receive the latest news about Paratek Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About PRTK
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.